Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous human insulin in the therapy of adult subjects with type 1 or type 2 diabetes mellitus and chronic asthma: a one-year, multicenter, randomized, outpatient, open-label, parallel-group comparative trial

X
Trial Profile

Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous human insulin in the therapy of adult subjects with type 1 or type 2 diabetes mellitus and chronic asthma: a one-year, multicenter, randomized, outpatient, open-label, parallel-group comparative trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 14 May 2010 Results presented at 106th International Conference of the American Thoracic Society.
    • 15 Dec 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 02 Dec 2008 Planned end date changed from 1 Oct 2008 to 1 Dec 2008, based on information from ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top